Assay Migrations: FDA Offers Streamlined Path To Switch Testing Platforms
This article was originally published in The Gray Sheet
Executive Summary
In an age of ever-accelerating automation, making lab tests available on new instrument platforms is a natural evolutionary step in the clinical diagnostics space. FDA issued draft guidelines Jan. 5 to help companies make these transitions while minimizing developmental burdens